Back to Search
Start Over
Clinical experience with radium-223 in the treatment of patients with advanced castrate-resistant prostate cancer and symptomatic bone metastases
- Source :
- Therapeutic Advances in Urology, Vol 8 (2016)
- Publication Year :
- 2016
- Publisher :
- SAGE Publications, 2016.
-
Abstract
- The treatment of metastatic castrate-resistant prostate cancer (mCRPC) has grown over the past decade. The majority of patients develop bone metastases, which pose a significant burden on morbidity and mortality, especially skeletal-related events. Whilst demonstrating a favourable safety profile and improving symptoms, radiopharmaceuticals have until recently failed to show a survival benefit. However, since the large phase III randomized ALSYMPCA trial, the calcium mimetic properties of radium-223 (Ra223) have improved patients’ quality of life and improved survival whilst keeping toxicities to a minimum. This review article summarizes the clinical data including our real life experience on the usage of the alpha emitter Ra223 in mCRPC, paying particular attention to how clinicians should best monitor response.
- Subjects :
- Radium-223
Oncology
medicine.medical_specialty
Urology
Castrate-resistant prostate cancer
Reviews
Improved survival
lcsh:RC870-923
030218 nuclear medicine & medical imaging
03 medical and health sciences
Prostate cancer
0302 clinical medicine
Quality of life
Prostate
Internal medicine
medicine
business.industry
lcsh:Diseases of the genitourinary system. Urology
medicine.disease
Review article
Surgery
medicine.anatomical_structure
Survival benefit
030220 oncology & carcinogenesis
business
medicine.drug
Subjects
Details
- ISSN :
- 17562880 and 17562872
- Volume :
- 8
- Database :
- OpenAIRE
- Journal :
- Therapeutic Advances in Urology
- Accession number :
- edsair.doi.dedup.....2b4aa0dccffa1bb0f9ee6657f5fc8bae